AstraZeneca: Why now could be the right time to invest - financial expert provides insight into opportunities and potential.

AstraZeneca: Why now could be the right time to invest - financial expert provides insight into opportunities and potential.

According to a report from www.aktienwelt360.de,

AstraZeneca recently acquired Gracell Biotechnologies for $1.2 billion, putting the company in an even stronger position in the Chinese market. This acquisition, along with other recent drug approvals in China, demonstrates the potential for growth and stability. In addition, AstraZeneca's management forecasts earnings growth of around 14% to 15% by 2024. In addition, the company has recorded an impressive increase in sales in recent years and has continuously invested in research and development.

The strategic move to acquire Gracell Biotechnologies could bring long-term benefits to AstraZeneca. Gracell is a pioneer in cancer research and integrating it into AstraZeneca's portfolio could bring huge benefits in the future. In addition, the licensing agreement with Eccogene for a drug to treat obesity shows the potential to enter new and fast-growing markets.

AstraZeneca has seen impressive sales growth in recent years and benefits from a stable gross margin of around 80%. This indicates efficient cost control and increased profitability. The company has also continued to increase its research and development spending, indicating a clear commitment to innovation and long-term growth.

The diversification of AstraZeneca's product portfolio minimizes risks and shows promising results in new anti-cancer applications. With an annual earnings per share growth rate of 11% to 14% by the end of the decade, AstraZeneca is well ahead of its competitors.

Still, as with any investment, there are risks to consider, especially in the pharmaceutical industry. Nevertheless, AstraZeneca remains financially strong and well valued on the market even after the Gracell takeover. According to a current valuation by www.aktienwelt360.de, the fair value of AstraZeneca shares is around 200 British pounds, while the current price is around 108 British pounds. This means the stock is undervalued by 46%.

Overall, AstraZeneca is an attractive option for investors looking for a mix of stability and growth potential, offering a cheap investment opportunity compared to its competitors and the broader market.